Cover Image
市場調查報告書

高膽固醇症:開發平台分析

Hypercholesterolemia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192645
出版日期 內容資訊 英文 214 Pages
訂單完成後即時交付
價格
Back to Top
高膽固醇症:開發平台分析 Hypercholesterolemia - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 214 Pages
簡介

高膽固醇症是由於血液中高濃度的膽固醇造成的。特別容易引發心血管疾病。膽固醇沈積在動脈,造成血管狹窄,限制血液的流通。致病因素有糖尿病、腎臟疾病、肥胖等各種疾病。此外還有遺傳、特定藥物、久坐的生活方式、抽煙、酒精成癮、緊張狀態、高脂肪食物等。常見的症狀有動脈閉塞、下肢疼痛、胸部疼痛、膽固醇沉積等。治療方法包含了改善生活方式、改善飲食、戒煙、投藥等。

本報告提供高膽固醇症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

高膽固醇症概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • 3SBio Inc.
  • Abeome Corporation
  • Aegerion Pharmaceuticals, Inc.
  • AFFiRiS AG
  • Alnylam Pharmaceuticals, Inc.
  • Alvogen Korea Co., Ltd.
  • AtheroNova Inc.
  • BioLingus AG
  • Catabasis Pharmaceuticals, Inc.
  • Cerenis Therapeutics Holding SA
  • Chong Kun Dang Pharmaceutical Corp.
  • CymaBay Therapeutics, Inc.
  • Daewon Pharm Co. Ltd.
  • Dybly AG
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Immune Response BioPharma, Inc.
  • Johnson & Johnson
  • Kadmon Corporation, LLC
  • Kastle Therapeutics, LLC
  • 興和
  • kyorin製藥
  • Merck & Co., Inc.
  • Omeros Corporation
  • Pfizer Inc.
  • Planet Biotechnology Inc.
  • Progenra, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • RegenxBio Inc.
  • Serometrix, LLC
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
  • Thetis Pharmaceuticals LLC .
  • Viking Therapeutics, Inc.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8697IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypercholesterolemia - Pipeline Review, H2 2016, provides an overview of the Hypercholesterolemia (Metabolic Disorders) pipeline landscape.

Hypercholesterolemia arises due to high levels of cholesterol in the blood. These abnormal levels may lead to various diseases especially cardiovascular diseases. Cholesterol deposit in the arteries and may cause the narrowing of blood vessels hence restricting the blood flow. The predisposing factors for hypercholesterolemia include various diseases such as diabetes mellitus, renal diseases, obesity etc. The other factors involved are heredity, certain drugs, sedentary lifestyle, smoking, alcoholism, stress and high fat diet. The symptoms for hypercholesterolemia include blocked arteries, leg pain, chest pain and cholesterol deposits. The disease can be controlled by lifestyle changes, dietary changes, and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypercholesterolemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypercholesterolemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypercholesterolemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 11, 13, 5, 1, 17, 8 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.Hypercholesterolemia.

Hypercholesterolemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hypercholesterolemia (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hypercholesterolemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hypercholesterolemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hypercholesterolemia (Metabolic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hypercholesterolemia (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hypercholesterolemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Hypercholesterolemia Overview
  • Therapeutics Development
  • Pipeline Products for Hypercholesterolemia - Overview
  • Pipeline Products for Hypercholesterolemia - Comparative Analysis
  • Hypercholesterolemia - Therapeutics under Development by Companies
  • Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes
  • Hypercholesterolemia - Pipeline Products Glance
  • Late Stage Products
  • Clinical Stage Products
  • Early Stage Products
  • Unknown Stage Products
  • Hypercholesterolemia - Products under Development by Companies
  • Hypercholesterolemia - Products under Investigation by Universities/Institutes
  • Hypercholesterolemia - Companies Involved in Therapeutics Development
  • 3SBio Inc
  • AFFiRiS AG
  • Akcea Therapeutics Inc
  • Alvogen Korea Co Ltd
  • ARMO Biosciences Inc
  • AstraZeneca Plc
  • BioLingus AG
  • Catabasis Pharmaceuticals Inc
  • Chong Kun Dang Pharmaceutical Corp
  • CymaBay Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Dicerna Pharmaceuticals Inc
  • Dybly AG
  • Esperion Therapeutics Inc
  • Gemphire Therapeutics Inc
  • Golden Biotechnology Corp
  • Hanmi Pharmaceuticals Co Ltd
  • Immune Response BioPharma Inc
  • Johnson & Johnson
  • Kadmon Corp LLC
  • Kyorin Pharmaceutical Co Ltd
  • Leading BioSciences Inc
  • LipimetiX Development Inc
  • Lotus Pharmaceutical Co Ltd
  • Merck & Co Inc
  • Pfizer Inc
  • Planet Biotechnology Inc
  • Progenra Inc
  • Regeneron Pharmaceuticals Inc
  • RegenxBio Inc
  • Serometrix LLC
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Solvotrin Therapeutics Ltd
  • The Medicines Company
  • Thetis Pharmaceuticals LLC
  • Viking Therapeutics Inc
  • Zhejiang Hisun Pharmaceutical Co Ltd
  • Hypercholesterolemia - Therapeutics Assessment
  • Assessment by Monotherapy Products
  • Assessment by Combination Products
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Drug Profiles
  • (aspirin + lisinopril + lovastatin) - Drug Profile
  • (atorvastatin calcium + ezetimibe) - Drug Profile
  • (atorvastatin calcium + ezetimibe) - Drug Profile
  • (atorvastatin calcium + TP-452) - Drug Profile
  • (bempedoic acid + ezetimibe) - Drug Profile
  • (candesartan cilexetil + rosuvastatin calcium) - Drug Profile
  • (ezetimibe + rosuvastatin calcium) - Drug Profile
  • AEM-28 - Drug Profile
  • AEM-2802 - Drug Profile
  • AEM-2814 - Drug Profile
  • alirocumab - Drug Profile
  • AM-0010 - Drug Profile
  • anacetrapib - Drug Profile
  • Antibodies for Metabolic Disorders - Drug Profile
  • Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
  • antroquinonol - Drug Profile
  • ATH-04 - Drug Profile
  • ATH-06 - Drug Profile
  • bempedoic acid - Drug Profile
  • BSN-272 - Drug Profile
  • CAT-2000 Series - Drug Profile
  • CAT-2003 - Drug Profile
  • colestilan chloride - Drug Profile
  • D-4F - Drug Profile
  • DCRPCSK-9 - Drug Profile
  • Drugs for Hypercholesterolemia - Drug Profile
  • Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile
  • DW-0929 - Drug Profile
  • DW-3102 - Drug Profile
  • DYB-186 - Drug Profile
  • EP-80317 - Drug Profile
  • evinacumab - Drug Profile
  • gemcabene calcium - Drug Profile
  • Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • HCP-1305 - Drug Profile
  • HGP-0816 - Drug Profile
  • HS-25 - Drug Profile
  • inclisiran - Drug Profile
  • IONIS-ANGPTL3LRx - Drug Profile
  • IR-1002 - Drug Profile
  • KD-026 - Drug Profile
  • MBX-8025 - Drug Profile
  • MGL-3196 - Drug Profile
  • MGL-3745 - Drug Profile
  • MN-002 - Drug Profile
  • Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • PF-06446846 - Drug Profile
  • Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • RGX-501 - Drug Profile
  • rosuvastatin calcium - Drug Profile
  • Small Molecule for Hypercholesterolemia - Drug Profile
  • Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile
  • Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • Small Molecules to Inhibit IDOL for Hypercholesterolemia - Drug Profile
  • Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
  • ST-0702 - Drug Profile
  • SX-PCK9 - Drug Profile
  • Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
  • Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile
  • VK-2809 - Drug Profile
  • volanesorsen sodium - Drug Profile
  • Hypercholesterolemia - Dormant Projects
  • Hypercholesterolemia - Discontinued Products
  • Hypercholesterolemia - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Hypercholesterolemia, H2 2016
  • Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Hypercholesterolemia - Pipeline by 3SBio Inc, H2 2016
  • Hypercholesterolemia - Pipeline by AFFiRiS AG, H2 2016
  • Hypercholesterolemia - Pipeline by Akcea Therapeutics Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Alvogen Korea Co Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by ARMO Biosciences Inc, H2 2016
  • Hypercholesterolemia - Pipeline by AstraZeneca Plc, H2 2016
  • Hypercholesterolemia - Pipeline by BioLingus AG, H2 2016
  • Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016
  • Hypercholesterolemia - Pipeline by CymaBay Therapeutics Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Daewon Pharm Co Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by Dicerna Pharmaceuticals Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Dybly AG, H2 2016
  • Hypercholesterolemia - Pipeline by Esperion Therapeutics Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Golden Biotechnology Corp, H2 2016
  • Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by Immune Response BioPharma Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2016
  • Hypercholesterolemia - Pipeline by Kadmon Corp LLC, H2 2016
  • Hypercholesterolemia - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by Leading BioSciences Inc, H2 2016
  • Hypercholesterolemia - Pipeline by LipimetiX Development Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by Merck & Co Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Pfizer Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Planet Biotechnology Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Progenra Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Hypercholesterolemia - Pipeline by RegenxBio Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Serometrix LLC, H2 2016
  • Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by Solvotrin Therapeutics Ltd, H2 2016
  • Hypercholesterolemia - Pipeline by The Medicines Company, H2 2016
  • Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2016
  • Hypercholesterolemia - Pipeline by Viking Therapeutics Inc, H2 2016
  • Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypercholesterolemia - Dormant Projects, H2 2016
  • Hypercholesterolemia - Dormant Projects (Contd..1), H2 2016
  • Hypercholesterolemia - Dormant Projects (Contd..2), H2 2016
  • Hypercholesterolemia - Dormant Projects (Contd..3), H2 2016
  • Hypercholesterolemia - Dormant Projects (Contd..4), H2 2016
  • Hypercholesterolemia - Dormant Projects (Contd..5), H2 2016
  • Hypercholesterolemia - Dormant Projects (Contd..6), H2 2016
  • Hypercholesterolemia - Discontinued Products, H2 2016
  • Hypercholesterolemia - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Hypercholesterolemia, H2 2016
  • Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top